Latest Vascular endothelial growth factor Stories
Desire for Greater Efficacy and Improved Convenience Drive Perceived Value of Emerging Therapies for Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON,
Ophthotech/Novartis's Fovista Will Exceed $500 Million in 2023 Sales as a Treatment for the Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Oct. 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.
-- Fourth indication for injection treatment that can stabilize and improve vision(1) -- mCNV a leading cause of visual impairment among those 20-50 years of age(9) Since
EYLEA Now Approved for Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Macular Edema following RVO TARRYTOWN, N.Y., Oct.
A major medical discovery by scientists at The University of Nottingham could lead to the development of an entirely new type of painkiller.
A single ILUVIEN implant provides treatment for three years ATLANTA, Sept. 29, 2014 /PRNewswire/ -- Alimera Sciences, Inc.
TARRYTOWN, N.Y., Sept. 22, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd.
Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass.,
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.